These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 2159864)
1. In vitro effect of YTR (tazobactam) on plasmid and chromosomally mediated beta-lactamases. Stobberingh EE Chemotherapy; 1990; 36(3):209-14. PubMed ID: 2159864 [TBL] [Abstract][Full Text] [Related]
2. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases. Akova M; Yang Y; Livermore DM J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496 [TBL] [Abstract][Full Text] [Related]
3. Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates. Stefani S; Castiglia P; Maida A; Muresu E; Mezzatesta ML; Nicoletti G J Chemother; 1990 Oct; 2(5):295-9. PubMed ID: 1965317 [TBL] [Abstract][Full Text] [Related]
4. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830). Jones RN; Barry AL Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422 [TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria. Chang SC; Hsu LY; Luh KT; Hsieh WC J Formos Med Assoc; 1991 Oct; 90(10):947-52. PubMed ID: 1685175 [TBL] [Abstract][Full Text] [Related]
6. Antibacterial activity of piperacillin and tazobactam against beta-lactamase-producing clinical isolates. Cullmann W; Stieglitz M Chemotherapy; 1990; 36(5):356-64. PubMed ID: 2170081 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin. Higashitani F; Hyodo A; Ishida N; Inoue M; Mitsuhashi S J Antimicrob Chemother; 1990 Apr; 25(4):567-74. PubMed ID: 2161820 [TBL] [Abstract][Full Text] [Related]
8. Mechanism of suppression of piperacillin resistance in enterobacteria by tazobactam. Kadima TA; Weiner JH Antimicrob Agents Chemother; 1997 Oct; 41(10):2177-83. PubMed ID: 9333044 [TBL] [Abstract][Full Text] [Related]
9. [Efficiency of tazobactam as inhibitor of beta-lactamases, combined with piperacillin, against resistant strains to this penicillin]. Roy C; Tirado M; Teruel D; Reig R; RÃ fols M Med Clin (Barc); 1989 Mar; 92(10):371-4. PubMed ID: 2541285 [TBL] [Abstract][Full Text] [Related]
10. Induction of chromosomal beta-lactamases by different concentrations of clavulanic acid in combination with ticarcillin. Stobberingh EE J Antimicrob Chemother; 1988 Jan; 21(1):9-16. PubMed ID: 3128523 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo efficacy of YTR-830H and piperacillin combinations versus beta-lactamase-producing bacteria. Kuck NA; Petersen PJ; Weiss WJ; Testa RT J Chemother; 1989 Jun; 1(3):155-61. PubMed ID: 2552030 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of piperacillin/tazobactam against 615 Pseudomonas aeruginosa strains isolated in intensive care units. Bonfiglio G; Laksai Y; Franceschini N; Perilli M; Segatore B; Bianchi C; Stefani S; Amicosante G; Nicoletti G Chemotherapy; 1998; 44(5):305-12. PubMed ID: 9732144 [TBL] [Abstract][Full Text] [Related]
13. Induction/inhibition of chromosomal beta-lactamases by beta-lactamase inhibitors. Moosdeen F; Keeble J; Williams JD Rev Infect Dis; 1986; 8 Suppl 5():S562-8. PubMed ID: 3026004 [TBL] [Abstract][Full Text] [Related]
14. [In vitro activity of tazobactam and piperacillin combination against 224 strains of Pseudomonas aeruginosa according to the production of beta-lactamase]. Thabaut A; Meyran M Pathol Biol (Paris); 1991 May; 39(5):361-6. PubMed ID: 1652726 [TBL] [Abstract][Full Text] [Related]
15. Behaviour of beta-lactamase-positive and -negative Staphylococcus aureus isolates in susceptibility tests with piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations. Bonfiglio G; Livermore DM J Antimicrob Chemother; 1993 Sep; 32(3):431-44. PubMed ID: 8262865 [TBL] [Abstract][Full Text] [Related]
16. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli. Jacobs MR; Aronoff SC; Johenning S; Shlaes DM; Yamabe S Antimicrob Agents Chemother; 1986 Jun; 29(6):980-5. PubMed ID: 3015017 [TBL] [Abstract][Full Text] [Related]
17. Beta-lactamase inhibitors: relation between kinetic data and in-vitro synergism studies. Cullmann W Zentralbl Bakteriol; 1991 Oct; 275(4):500-3. PubMed ID: 1661596 [TBL] [Abstract][Full Text] [Related]
18. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors. Qadri SM; Ueno Y; Cunha BA Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model. Nicasio AM; VanScoy BD; Mendes RE; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689 [TBL] [Abstract][Full Text] [Related]
20. In vitro synergy studies based on tazobactam/piperacillin against clinical isolates of metallo-beta-lactamase-producing Pseudomonas aeruginosa. Fujimura S; Takane H; Nakano Y; Watanabe A J Antimicrob Chemother; 2009 Nov; 64(5):1115-6. PubMed ID: 19744981 [No Abstract] [Full Text] [Related] [Next] [New Search]